---
layout: post
title: "Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability"
date: 2026-02-04 21:37:02 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-22211
original_published: 2025-12-08 00:00:00 +0000
significance: 8.00
---

# Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 08, 2025 00:00 UTC
**Document Number:** 2025-22211

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Genentech, Inc. (Genentech) for Actemra (tocilizumab). FDA revoked this Authorization on August 8, 2025, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, including an explanation of the reasons for the revocation, are reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/08/2025-22211/revocation-of-emergency-use-of-a-drug-product-during-the-covid-19-pandemic-availability)
- API: https://www.federalregister.gov/api/v1/documents/2025-22211

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
